Patricia Z.
- Country
- France
- Department
- Oncologie
Research Overview
- Phase 3 Study of Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid in Acute Myeloid Leukemia Patients Aged 18-60
- Minimal Residual Disease-Adapted Strategy in Multiple Myeloma: Evaluation of Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone in Transplant-Eligible Patients
- Phase 3 Study Evaluating Elranatamab-Lenalidomide Efficacy in Newly Diagnosed Multiple Myeloma Compared to Standard Chemotherapy and Maintenance Therapy
Data & Insights
Has run more than one trial at 57 of 86 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in the treatment of acute myeloid leukemia and multiple myeloma, with particular emphasis on developing innovative therapeutic strategies.
- Adult AML Treatment Optimization
- Multiple Myeloma Therapy Advancement
- Novel Drug Combinations
The research focuses on improving survival outcomes in adults with blood cancers through targeted therapeutic approaches.
Stem Cell Therapy
Expertise in stem cell transplantation and cellular therapy, including both autologous and allogeneic transplantation procedures for hematologic conditions.
- Transplant Conditioning Protocols
- Graft versus Host Disease Prevention
- Maintenance Strategies
The investigator explores innovative approaches in transplantation medicine and cellular therapy applications.
Disease Monitoring
Specialized focus on minimal residual disease (MRD) assessment and monitoring strategies in hematologic malignancies.
- MRD-Guided Treatment Approaches
- Advanced Disease Monitoring
- Treatment Response Assessment
Emphasis on utilizing sophisticated monitoring techniques to guide therapeutic decision-making and improve patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.